IMV Announces Board Retirement
Mr. Scardino, 71, joined the board in 2011 and served as Chairman from 2011 to 2016. After a career in journalism in the US and the
“It has been a source of humility to work with so many talented scientists and committed shareholders for so many years,” Mr. Scardino said. “The discoveries in immunology made by the science faculty at
IMV’s Board and Management thank him for his dedication and support of the Company and wish Albert well in all his future endeavors.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals.
Marc Jasmin, Senior Director, Investor Relations, IMV
O: (902) 492-1819 ext. 1042
M: (514) 617-9481
Josh Rappaport, Director, Stern IR
O: (212) 362-1200
Delphine Davan, Director, Communications, IMV
M: (514) 968-1046